Autonomic dysfunction in dementia with Lewy bodies

Thaisetthawatkul, Pariwat; Boeve, Bradley F.; Benarroch, Eduardo E.; Sandroni, Paola; Ferman, Tanis J.; Petersen, Ronald C.; Low, P. A.

doi:10.1212/01.wnl.0000125192.69777.6d

Cited by 180 publications

(99 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Thus, A5 neurons appear to participate in complex cardiorespiratory interactions, including those associated with sympathetic responses to hypoxia. Therefore, it is conceivable that involvement of these neurons may contribute to respiratory [8,26] or cardiovascular [25] manifestations of MSA. However, given that the role of A5 neurons is not fully characterized by experimental studies, our conclusions regarding their potential contribution to cardiorespiratory manifestations of MSA are speculative at this point.…”

Section: Discussionmentioning

confidence: 99%

Loss of A5 noradrenergic neurons in multiple system atrophy

et al. 2008

View full text Add to dashboard Cite

The A5 noradrenergic group of the pons projects on the medulla and spinal cord and contributes to control of sympathetic activity and respiration. Because these functions are affected in multiple system atrophy (MSA), we sought to determine whether there was involvement of A5 neurons in this disorder. We counted tyrosine-hydroxylase (TH) immunoreactive neurons in the A5 area and locus ceruleus in the pons obtained from six patients with clinical and neuropathological diagnoses of MSA and six age-matched controls using stereological methods. There was a severe loss of A5 neurons in MSA (total cell number 3,215 ± 258 in controls and 321 ± 62 in MSA, P < 0.001). The severity of cell loss was comparable to that of locus ceruleus neurons in these cases. Our results indicate that A5 neurons are severely affected in MSA and this may contribute to some of the manifestations of this synucleinopathy.

show abstract

Section: Discussionmentioning

confidence: 99%

Loss of A5 noradrenergic neurons in multiple system atrophy

et al. 2008

View full text Add to dashboard Cite

show abstract

“…A variety of noninvasive or minimally invasive procedures have been proposed to distinguish PD from parkinsonian syndromes. Twelve Class III articles [21][22][23][24][25][26][27][28][29][30][31] were identified (table E-3). In these studies, diagnosis of PD or other parkinsonian syndromes were based on clinical criteria.…”

Section: Analysis Of the Evidence Question 1: Which Clinical Featurementioning

confidence: 99%

“…29 Using the Composite Autonomic Severity Score (CASS), patients with DLB had dysautonomia intermediate between MSA and PD.…”

Section: Analysis Of the Evidence Question 1: Which Clinical Featurementioning

confidence: 99%

Practice Parameter: Diagnosis and prognosis of new onset Parkinson disease (an evidence-based review) [RETIRED]

et al. 2006

View full text Add to dashboard Cite

Abstract-Objective:To define key issues in the diagnosis of Parkinson disease (PD), to define features influencing progression, and to make evidence-based recommendations. Two clinical questions were identified: 1) Which clinical features and diagnostic modalities distinguish PD from other parkinsonian syndromes? 2) Which clinical features predict rate of disease progression? Methods: Systematic review of the literature was completed. Articles were classified according to a four-tiered level of evidence scheme. Recommendations were based on the evidence. Results and Conclusions: 1. Early falls, poor response to levodopa, symmetry of motor manifestations, lack of tremor, and early autonomic dysfunction are probably useful in distinguishing other parkinsonian syndromes from Parkinson disease (PD). 2. Levodopa or apomorphine challenge and olfactory testing are probably useful in distinguishing PD from other parkinsonian syndromes. 3. Predictive factors for more rapid motor progression, nursing home placement, and shorter survival time include older age at onset of PD, associated comorbidities, presentation with rigidity and bradykinesia, and decreased dopamine responsiveness. Future research into methods for earlier and more accurate diagnosis of the disease and identification and clarification of predictive factors of rapid disease progression is warranted. NEUROLOGY 2006;66:968-975

show abstract

“…Распро-страненность ее в общей популяции среди лиц стар-ше 50 лет составляет 5%, среди лиц старше 70 лет -30%. Частота ОГ в патоморфологически подтверж-денных случаях ДТЛ составляет 38-93% [20,21]. ОГ приводит к частым падениям, обморокам, гипопер-фузии головного мозга, тем самым усугубляя тече-ние заболевания.…”

unclassified

Orthostatic hypotension in dementia with Lewy bodies

Чимагомедова¹,

Левин²

2016

Z. nevrol. psikhiatr. im. S.S. Korsakova

View full text Add to dashboard Cite

ГБОУ ДПО «Российская медицинская академия последипломного образования», Москва, Россия В обзоре рассматриваются особенности проявления ортостатической гипотензии при деменции с тельцами Леви и методы ее диагностики. Ранняя диагностика данных нарушений позволит предотвратить такие нежелательные последствия, как падения и обмороки, улучшить повседневную деятельность и повысить качество жизни пациентов. анализируются современные подходы к коррекции данного состояния. The features of orthostatic hypotension in patients with dementia with Lewy bodies are considered. The early diagnosis of these disorders could prevent adverse conditions (falls and syncopes), improve activities of daily living and quality-of-life. Current approaches to treatment of orthostatic hypotension are analyzed.

show abstract

Autonomic dysfunction in dementia with Lewy bodies

Abstract: Autonomic dysfunction is frequent in dementia with Lewy bodies and the severity is intermediate between that of multiple system atrophy and Parkinson disease.

Cited by 180 publications

References 28 publications

Loss of A5 noradrenergic neurons in multiple system atrophy

Loss of A5 noradrenergic neurons in multiple system atrophy

Practice Parameter: Diagnosis and prognosis of new onset Parkinson disease (an evidence-based review) [RETIRED]

Orthostatic hypotension in dementia with Lewy bodies

Contact Info

Product

Resources

About